Poseida Therapeutics, Inc. Quarterly Earnings Per Share, Basic in USD/shares from Q2 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD/shares
Description
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Summary
Poseida Therapeutics, Inc. quarterly/annual Earnings Per Share, Basic history and growth rate from Q2 2021 to Q3 2024.
  • Poseida Therapeutics, Inc. Earnings Per Share, Basic for the quarter ending September 30, 2024 was 0.21 USD/shares.
  • Poseida Therapeutics, Inc. Earnings Per Share, Basic for the twelve months ending September 30, 2024 was -0.61 USD/shares, a 53.4% increase year-over-year.
  • Poseida Therapeutics, Inc. annual Earnings Per Share, Basic for 2023 was -1.37 USD/shares, a 53.9% decline from 2022.
  • Poseida Therapeutics, Inc. annual Earnings Per Share, Basic for 2022 was -0.89 USD/shares, a 55.7% increase from 2021.
Earnings Per Share, Basic, Trailing 12 Months (USD/shares)
Earnings Per Share, Basic, Quarterly (USD/shares)
Earnings Per Share, Basic, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$1 $0.21 +$0.56 Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$1 $0 $0 0% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 -$1 $0 +$0.20 +44.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$1 $0 $0 -31.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 -$1 $0 -$1 -138% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $0 $0 +$0.37 +53.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 $0 $0 +$0.48 +51.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$1 $0 Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 $0.92 +$1.60 Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$1 +$0.05 +6.76% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$1 Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q3 2021 -$1 Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$1 Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.